Renaissance Technologies’s INmune Bio INMB Stock Holding History

Renaissance Technologies’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$48.4K	Buy	29,700 +12,700	+75%	+$17.6K	﹤0.01%	3049
2026 Q1	$19.2K	Buy	+17,000	New	+$24.2K	﹤0.01%	3171
2025 Q1	–	Sell	-185,800	Closed	-$868K	–	3641
2024 Q4	$868K	Buy	185,800 +78,600	+73%	+$410K	﹤0.01%	2573
2024 Q3	$578K	Buy	+107,200	New	+$762K	﹤0.01%	2720
2023 Q3	–	Sell	-20,000	Closed	-$182K	–	3876
2023 Q2	$182K	Sell	20,000 -14,800	-43%	-$119K	﹤0.01%	3325
2023 Q1	$225K	Buy	+34,800	New	+$280K	﹤0.01%	3228
2022 Q3	–	Sell	-32,100	Closed	-$284K	–	4214
2022 Q2	$284K	Buy	+32,100	New	+$239K	﹤0.01%	3482
2020 Q4	–	Sell	-40,000	Closed	-$412K	–	3541
2020 Q3	$412K	Buy	+40,000	New	+$407K	﹤0.01%	2886

Other funds holding INMB

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Renaissance Technologies's INMB Position: Q2 2026 in Review

Renaissance Technologies increased its INmune Bio (INMB) stake by 75% in Q2 2026, buying an estimated $17.6K and bringing the position to 29,700 shares worth $48.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3049.

Renaissance Technologies first reported a position in INMB in Q3 2020 and has held it in 8 quarters since. The position peaked at $868K in Q4 2024. 83 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

Renaissance Technologies held 29,700 shares of INmune Bio worth $48.4K as of Q2 2026.
Renaissance Technologies bought 12,700 INmune Bio shares in Q2 2026, an estimated $17.6K.
INmune Bio made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #3049 holding.
Renaissance Technologies first reported a position in INmune Bio in Q3 2020 and has held it in 8 quarters since.
Renaissance Technologies's INmune Bio position peaked at $868K in Q4 2024.
83 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.